We are live on ! Find out more
FBRX icon

Forte Biosciences

57 hedge funds and large institutions have $12.8M invested in Forte Biosciences in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 14

1.44% less ownership

Funds ownership: 2.55%1.11% (-1.4%)

24% less funds holding

Funds holding: 7557 (-18)

45% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 38

53% less call options, than puts

Call options by funds: $1.32M | Put options by funds: $2.8M

96% less capital invested

Capital invested by funds: $289M → $12.8M (-$276M)

Holders
57
Holders Change
-18
Holders Change %
-24%
% of All Funds
1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
21
Increased
16
Reduced
14
Closed
38
Calls
$1.32M
Puts
$2.8M
Net Calls
-$1.48M
Net Calls Change
-$1.48M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$2.28M -$75.3K -136 -0.4%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.65M +$716K +1,292 +6%
Millennium Management
3
Millennium Management
New York
$1.5M +$10.8M +19,447 +2,549%
State Street
4
State Street
Massachusetts
$1.37M +$6.26M +11,293 +155%
N
5
Nuveen
North Carolina
$1.35M +$79.8K +144 +8%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$664K +$4.97M +8,969 New
WP
7
Woodline Partners
California
$424K -$1.12M -2,023 -26%
OQS
8
Occudo Quantitative Strategies
Florida
$417K +$3.12M +5,632 New
Jane Street
9
Jane Street
New York
$344K +$2.57M +4,643 New
PPA
10
Parametric Portfolio Associates
Washington
$329K +$2.02M +3,644 +454%
Northern Trust
11
Northern Trust
Illinois
$313K +$1.49M +2,693 +175%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$300K -$1.71M -3,083 -43%
Citadel Advisors
13
Citadel Advisors
Florida
$155K +$940K +1,696 +430%
GCP
14
GSA Capital Partners
United Kingdom
$152K +$1.14M +2,051 New
Group One Trading
15
Group One Trading
Illinois
$112K +$841K +1,518 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$103K +$161K +290 +26%
SFI
17
Susquehanna Fundamental Investments
Pennsylvania
$97K +$725K +1,308 New
Wolverine Trading
18
Wolverine Trading
Illinois
$95K +$688K +1,241 New
JG
19
Jefferies Group
New York
$94.4K +$707K +1,276 New
Charles Schwab
20
Charles Schwab
California
$84K +$19.4K +35 +3%
Parallax Volatility Advisers
21
Parallax Volatility Advisers
California
$79K +$590K +1,065 New
Voloridge Investment Management
22
Voloridge Investment Management
Florida
$77K +$579K +1,045 New
SSA
23
Schonfeld Strategic Advisors
New York
$68K +$510K +920 New
TSS
24
Two Sigma Securities
New York
$57K +$429K +774 New
NC
25
NinePointTwo Capital
California
$54K +$409K +739 New

FBRX Hedge Fund Activity: Q3 2021 in Review

57 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q3 2021, worth a combined $12.8M — down 96% from $289M a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of FBRX and 21 opened new positions — a net loss of 17 holders — while 14 trimmed existing stakes and 16 added.

The largest buyer was Millennium Management, adding an estimated $10.8M. The largest seller was Fred Alger Management, exiting entirely with an estimated $40.9M sold.

  • 57 institutional investors held Forte Biosciences (FBRX) as of Q3 2021, down from 75 in Q2 2021.
  • Funds reported $12.8M of Forte Biosciences stock for Q3 2021, down 96% quarter-over-quarter.
  • 21 funds opened new Forte Biosciences positions in Q3 2021 and 38 closed out, a net change of -17 holders.
  • The largest Forte Biosciences buyer in Q3 2021 was Millennium Management, an estimated $10.8M added.
  • The largest Forte Biosciences seller in Q3 2021 was Fred Alger Management, an estimated $40.9M sold.

Based on aggregated 13F filings for Q3 2021.